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ABSTRACT 
BACKGROUND: EPA has been clinically shown to reduce muscle wasting during cancer 
cachexia.  This study investigates whether curcumin or green tea extract (GTE) enhances the 
ability of low doses of eicosapentaenoic acid (EPA) to reduce loss of muscle protein in an in 
vitro model.  
METHODS: A low dose of EPA with minimal anti-cachectic activity was chosen to evaluate 
any potential synergistic effect with curcumin or GTE. Depression of protein synthesis and 
increase in degradation was determined in C2C12 myotubes in response to tumour necrosis 
factor-α (TNF-α) and proteolysis-inducing factor (PIF).  
RESULTS: EPA (50 μM) or curcumin (10 μg ml-1) alone had little effect on protein 
degradation caused by PIF but the combination produced complete inhibition, as did the 
combination with GTE (10 μg ml-1). In response to TNF-α (25 ng ml-1)-induced protein 
degradation, EPA had a small, but not significant effect on protein degradation, however, 
when curcumin and GTE were combined with EPA the effect was enhanced. EPA completely 
attenuated the depression of protein synthesis caused by TNF-α, but not that caused by PIF.   
The combination of EPA with curcumin produced a significant increase in protein synthesis 
to both agents. GTE alone or in combination with EPA had no effect on the depression of 
protein synthesis by TNF-α, but did significantly increase protein synthesis in PIF-treated 
cells. Both TNF-α and PIF significantly reduced myotube diameter from 17 to 13 μm for TNF- 
α (23.5%) and 15 μm (11.8%) for PIF  However the triple combination of EPA, curcumin and 
GTE returned diameters to values not significantly different  from the control.  
CONCLUSION: These results suggest that either curcumin or GTE or the combination could 
enhance the anticatabolic effect of EPA on lean body mass. 
Keywords: muscle protein atrophy; EPA; curcumin; green tea extract.  
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INTRODUCTION 
At least half of all cancer patients suffer from cachexia, a progressive wasting 
syndrome involving loss of both adipose tissue and skeletal muscle, which eventually leads 
to the death of the patient (Bachmann et al, 2008; Dewys et al, 1980). Although anorexia is 
initially present, provision of excess calories alone has a limited effect on weight loss (Koretz 
2007), and is considered to arise from the catabolic effect of cytokines such as tumour 
necrosis factor-α (TNF-α) and tumour products such as proteolysis-inducing factor (PIF). 
Thus treatment necessitates inclusion of an anti-catabolic agent in addition to nutritional 
support. 
 Eicosapentaenoic acid (EPA), a constituent of fish oil, is one such anti-catabolic agent 
shown to reduce production of the cytokine interleukin (IL)-6 but not TNF-α in serum, and 
the urinary excretion of PIF in cachectic patients with pancreatic cancer (Barber et al, 2001). 
EPA has also been shown to attenuate the catabolic effect of PIF, both in vitro (Smith et al, 
1999), and in vivo (Hussey and Tisdale, 1999). In vitro (Smith et al, 1999) and in vivo studies 
in mice (Smith et al, 2004) suggest that EPA is effective in attenuation of the increased 
protein degradation in cachexia. It has no effect alone on protein synthesis, although its 
effect can be enhanced with casein and amino acids (Smith et al, 2004). For this reason 
commercial EPA containing oral nutrition supplements (EPA-ONS) for the treatment of 
cancer cachexia have fish oil combined with high protein levels (Barber et al, 1999). When 
consumed at 2.1 g EPA day-1 such a preparation is effective in increasing body weight in 
patients with pancreatic cancer, as well as increasing lean body mass (Barber et al, 1999). 
However, in larger scale clinical trials consumption was much less (1.5 g EPA day-1)and the 
beneficial effect was reduced (Fearon et al, 2003), although a study of patients with non-
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small cell lung cancer (NSCLC) undergoing multimodality treatment showed that EPA-ONS 
intake of 1g day-1 had a better maintenance of body weight (van der Meij et al, 2010), fat 
free mass, quality of life, and performance status than standard ONS (van der Meij et al, 
2012).  In another study of NSCLC patients undergoing chemotherapy, better weight 
maintenance and FFM gain were shown with EPA-ONS (72% of patients consumed 2.2 
g/day) compared to the control group (Sanchez et al, 2014).  An esophageal cancer surgery 
study showed that all aspects of body composition were maintained with EPA-ONS while 
patients receiving a standard supplement lost significant amounts of FFM (Ryan et al, 2009). 
 With increased cost, poor patient compliance and limited sources of fish oil, 
methods of increasing the activity of EPA would be beneficial. For example, the activity of 
EPA could be enhanced if combined with other anti-catabolic agents. In this study two 
agents previously shown to exert anti-cachexia activity in experimental models were 
studied; curcumin (diferuloylmethane) (Siddiqui et al, 2009) and green tea extract (GTE) 
containing epigallocatechin-3-gallate-(EGCg) and other catechins (Wang et al, 2011). Both 
curcumin (Wyke et al, 2004) and EGCg (Mirza et al, 2014) were shown to attenuate the 
catabolic effect of PIF and TNF-α on muscle protein degradation in vitro and this study 
investigates their ability to act in combination with EPA to attenuate the depression of 
protein synthesis and protein degradation produced by these catabolic factors in C2C12 
murine myotubes. 
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METHODS AND METHODS 
Materials 
The chymotrypsin substrate (N-Succinyl-Leu-Leu-Val-Tyr-7-Amido-4-methylcoumarin) was 
obtained from Sigma (Dorset, UK). L-[2,6-3H] phenylalanine (sp.act.3.7 TBqmmol-1) was from 
Perkin Elmer (Cambridge, UK). Mouse monoclonal antibodies to 20S proteasome α-subunits 
and p42 were from Affiniti Research Products (Exeter, UK). Fatty acid free BSA, tumour 
necrosis factor (TNF-α), polyclonal rabbit antibody to mouse β-actin, chymotrypsin substrate 
(N-Succinyl-Leu-Leu-Val-Tyr-7-Amido-4-methylcoumarin) and lactacystin were purchased 
from Sigma-Aldridge (Dorset, UK). Peroxidase-conjugated sheep antirabbit and antimouse 
antibodies were purchased from GE Healthcare (Bucks, UK), as were Hybond A 
nitrocellulose membranes. Enhanced chemiluminescence (ECL) development kits were from 
Pierce through Thermo Fischer Scientific (Northumberland, UK). Rabbit polyclonal antisera 
to atrogin-1/MAFbx, and goat polyclonal antisera to MuRF1 were purchased from Santa 
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). EPA was added to fatty acid free BSA in 
doubled distilled water (g/g) and neutralised with equimolar NaHCO3. Green tea extract 
(Sunphenon 90D) was purchased from Taiyo international, (Tokyo, Japan). Curcumin C3 was 
from Sabinsa Corporation, NJ, USA. EPA (free acid) (98> %pure) was from Enzo Life Sciences 
(Exeter, UK). 
 
Measurement of proteasome activity 
Functional 20S proteasome activity was determined as the “chymotrypsin-like” enzyme 
activity by the release of 7-amino-4-methylcoumarin (AMC) from the fluorogenic peptide 
succinyl-LLVY-7-AMC as previously described (Whitehouse and Tisdale 2003). Activity was 
measured in the absence and presence of the specific proteasome inhibitor lactacystin 
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(10 μM) and only lactacystin suppressible activity was considered to be proteasome specific. 
The activity was normalised to the protein content which was determined using the 
Bradford assay (Sigma). 
 
Western blotting 
Myotubes were scraped from the substratum and washed with PBS prior to sonication at 
4°C in 20mM Tris-HCl (pH 7.4), 2mM ATP, 5mM MgCl2 and 1mM DTT. Cytosolic protein (10-
15 μg) formed by centrifugation at 18 000 g for 10 min at 4°C was resolved on 10% SDS–
PAGE at 180V for 1 h, followed by transference onto 0.45 mm nitrocellulose membranes at 
300mA for 1 h, which were then blocked with 5% Marvel in Tris–buffered saline, pH 7.5, at 
4 °C overnight. Both primary and secondary antibodies were used at a dilution of 1:1000. 
Incubation with primary antibodies was overnight at 4°C, while with secondary antibodies it 
was for 1h at room temperature, and development was by ECL. Blots were scanned by a 
densitometer to quantitate differences, and were reported relative to an actin loading 
control. 
 
Measurement of total protein degradation  
This was performed as previously described (Whitehouse and Tisdale, 2003).  Briefly 
myotubes were labelled for 24h with L-[2,6-3H] phenylalanine and then washed extensively 
in PBS followed by a further incubation for 2h to eliminate degradation of short-lived 
proteins.  Protein degradation was determined over a 24h period in the presence of 2mM 
non-labelled phenylalanine to prevent reincorporation of radioactivity, as a fraction of the 
total radioactivity incorporated into the myotubes in the presence or absence of PIF and 
TNF-α. Some myotubes were also treated with GTE, Curcumin and EPA for 2h prior to PIF or 
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TNF-α addition. The radioactivity released was expressed as a fraction of the total 
incorporated into the myotubes. 
Measurement of protein synthesis  
Myotubes were formed in six-well multiwell dishes, and were supplemented with DMEM 
without HS for 18 h before experimentation (Eley and Tisdale, 2007).  Curcumin, GTE and 
EPA were added to the cultures 2h before adding PIF and TNF-α. Protein synthesis was 
carried out after 4h incubation with PIF and TNF-α. Protein synthesis was determined by the 
incorporation of L-[2,6-3H] phenylalanine into myotubes over a 4h periods described in the 
figure legend. Protein synthesis was calculated as the radioactivity incorporated into acid 
(0.2 M perchloric acid) insoluble material as a percentage, compared with control cultures 
with no serum. 
Measurement of myotube diameter 
C2C12 myotubes were differentiated in DMEM medium with 2% horse serum. EPA, Curcumin 
and GTE were added to the cultures 2h before adding PIF and TNF-α on day 1, and the 
addition was repeated every 2 days. Myotube diameter was measured using an inverted 
widefield fluorescent microscope (Leica Microsystems GmbH, Germany). Analysis of the 
images was obtained using Leica application suit AF software.     
Statistical analysis 
Results are expressed as mean values +s.e.m for at least three replicate experiments. 
Differences in mean values between group were determined by one-way ANOVA followed 
by Tukey-Kramer multiple comparison test and p-values <0.05 were considered significant. 
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RESULTS 
Previous studies (Wyke et al, 2004) have shown the optimal concentration of PIF to initiate 
protein degradation in vitro to be 4.2 nM, while for TNF-α the optimal concentration is 25 
ng ml-1 (Mirza et al, 2014). The effect of increasing concentration of curcumin on protein 
degradation induced by TNF-α and PIF is shown in Fig 1*A, B+. The minimum effective 
concentration to attenuate protein degradation by both agents was 10 μg ml-1. For GTE the 
concentrations were 10 and 5 μg ml-1 for TNF-α and PIF respectively (Fig 1C, D). A 
concentration of 10 μg ml-1 for both curcumin and GTE was chosen for further studies. 
 The effect of combination of curcumin and GTE with EPA (50 μM) on protein 
degradation induced by PIF and TNF-α is shown in Fig 2. For PIF (Fig 2A) EPA alone had a 
small, but not significant effect on protein degradation, which was also shown by curcumin 
(10 μg ml-1), but the combination of EPA with curcumin totally attenuated PIF-induced 
protein degradation. A similar effect was seen with GTE at 10 μg ml-1 (Fig 2B), with the 
combination with EPA producing complete inhibition of PIF-induced protein degradation. 
For TNF-α, EPA alone attenuated protein degradation to control values, (Fig 2D), and this 
was further reduced in combination with curcumin (Fig 2C). GTE alone significantly reduced 
protein degradation induced by TNF-α (Fig 2D) and in combination with EPA, values were 
reduced below those in the negative control (Fig 2D). 
 The major degradative pathway for muscle protein in cachexia is considered to be 
the ubiquitin proteasome system. The functional activity of the proteasome can be 
measured as the chymotrypsin-like enzyme activity located on the β5-subunit of the 20S 
proteasome. The activity of this enzyme was enhanced by both TNF-α and PIF (Fig 3A, B), 
and reduced below the negative control by EPA, curcumin and GTE as well as combinations. 
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 TNF-α also increased protein expression of the 20S proteasome subunits as well as 
p42, an ATPase subunit of the 19S regulator, (Fig 4A, B) and the E3 ligases MuRF1 and 
MAFbx (Fig 4C, D), as determined by western blotting  and these were reduced to or below 
the negative control by EPA, curcumin, GTE and the combinations. Similar results were 
obtained with PIF (data not shown). 
 Both TNF-α and PIF depressed protein synthesis by 20% (Fig 5). Interestingly EPA 
completely attenuated the depression of protein synthesis induced by TNF-α (Fig 5A), but 
had no significant effect on that induced by PIF (Fig 5B), as previously reported (Smith et al, 
1999), possibly reflecting the different mechanism of action of the two agents. Curcumin 
alone was unable to reverse the depression of protein synthesis by TNF-α (Fig 5A) or PIF (Fig 
5B), but in combination with EPA there was a significant increase in protein synthesis. 
Neither GTE alone, or in combination with EPA had any significant effect on the depression 
of protein synthesis by TNF-α, while for PIF only the combination produced a significant 
increase of protein synthesis over that of PIF alone (Fig 5B). The effect of TNF-α and PIF on 
myotube diameter is shown in Fig 6. For TNF-α myotube diameter initially decreased and 
then stabilized at a significantly lower level than control (Fig 6A), However, myotube 
diameter was significantly increased  when TNF-α was combined with EPA, curcumin and 
GTE, such that values did not differ significantly from non-treated control (Fig 6A). A similar 
result was seen with PIF (Fig 6B), which significantly reduced myotube diameter alone, but 
this was restored to control values in the presence of EPA, curcumin and GTE. 
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DISCUSSION 
 Treatment for cachexia is currently limited and mainly involves use of megestrol 
acetate (Megace), an appetite stimulant which has been reported to increase body weight 
(Mantovani et al, 2011). However, this weight gain has been shown to be due to fat and 
water increases and not lean body mass (Loprinzi et al, 1993). In contrast EPA, has been 
shown to increase lean body mass, with no change in fat mass in patients with pancreatic 
cancer (Barber et al, 1999). There are several potential anti-cachectic agents, which have 
been identified from animal models, which have not yet been clinically evaluated. Among 
them are curcumin (Siddiqui et al, 2009) and GTE (Wang et al, 2011), both natural products 
found in turmeric and green tea respectively. These agents could potentially be used as 
alternative to EPA or combined with EPA to enhance its effectiveness as an anti-cachectic 
agent. To evaluate this possibility this study has employed murine myotubes as a surrogate 
model of skeletal muscle and muscle protein degradation and depressed protein synthesis 
have been initiated with two catabolic agents, TNF-α and PIF, both of which have been 
suggested to be important mediators of muscle loss in cancer patients with cachexia 
(Tisdale, 2009). Based on previous studies, a low dose of EPA with minimal anti-cachectic 
activity has been chosen to evaluate potential synergistic effect in combination with 
curcumin or GTE. 
 For protein degradation induced by both PIF and TNF-α, both curcumin and GTE 
enhanced the anti-catabolic effect of EPA at minimally effective concentrations. A similar 
effect was seen on the major components of the ubiquitin proteasome pathway, with both 
TNF-α and PIF enhancing expression of the 20S and 19S proteasome subunits as well as the 
ubiquitin ligases MuRF1 and MAFbx, which was attenuated by EPA, curcumin, GTE and the 
combination. We have also determined muscle protein atrophy by measuring myotube 
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diameter, which was significantly reduced by both TNF-α and PIF and restored by a 
combination of EPA, curcumin and GTE. Interestingly curcumin has been shown to block 
muscle proteolysis in septic rats without affecting the expression of atrogin-1 and MuRF1 
(Poylin et al, 2008). In addition to proteasome activity, protein breakdown by both calpain 
and cathepsin-L were also reduced by curcumin. In contrast, in mice bearing the cachexia-
inducing MAC16 tumour, curcumin attenuated loss of muscle protein by inhibiting 20S 
proteasome expression and reducing expression of MuRF1 and MAFbx (Siddiqui et al, 2009). 
Both EPA (Whitehouse and Tisdale, 2003) and curcumin (Alamdari, 2009; Thaloor et al. 
1999) attenuate protein degradation through the ubiquitin-proteasome pathway via the 
nuclear transcription factor NF-κB. Both inhibit the upstream kinase IκB kinase (IKK) thus 
preventing phosphorylation of inhibitor κBα (IκBα) in the cytosol, stabilising the NF-κB/IκB 
complex and preventing nuclear migration of NF-κB, which upregulates proteasomal 
expression (Wyke et al, 2004). However, curcumin also directly inhibits the chymotrypsin-
like activity of the 20S proteasome (Milacic et al, 2008), a feature also seen with the major 
polyphenols found in GTE (Smith et al, 2002). In addition Waag et al, (2011) has shown that 
these polyphenols also regulate expression of NF-κB, suggesting multiple mechanisms by 
which myofibrillar protein degradation may be suppressed. Both PIF and TNF-α depressed 
protein synthesis by the same amount and for TNF-α this depression in protein synthesis 
was attenuated by EPA, but not for PIF. This may be indicative of different mechanisms for 
depression of protein synthesis by the two agents, although studies to date suggest that 
they also share similar mechanisms by inducing autophosphorylation of the RNA-dependent 
protein kinase (PKR), which increases phosphorylation of eukaryotic initiation factor 2α 
(elF2α), which depresses protein synthesis by inhibiting binding of initiator methionyl-tRNA 
to the 40S ribosomal subunit (Eley and Tisdale, 2007; Eley et al, 2008). 
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These results suggest that the combinations of EPA with either curcumin or GTE, or both, 
would be effective in attenuating muscle protein degradation in cancer cachexia induced 
either by TNF-α or PIF. 
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Figure 1. Total protein degradation in C2C12 myotubes in response to treatment TNF-α (25 ng ml
-1) (A, 
C) or PIF (4.2 nM) (B, D) in the presence of curcumin (A, B) or GTE (C, D). Protein degradation was 
determined by the release of [3H] phenylalanine from pre-labelled cells over a 24h period. The 
experiment was repeated three times. Differences from the negative control with no additions is 
indicated as * p<0.05 and *** p<0.001, while differences from TNF-α or PIF are shown as Ϯ p<0.05, 
ϮϮ, p<0.01 or ϮϮϮ p<0.001. 
Figure 2. Total protein degradation in C2C12 myotubes in response to treatment with PIF (4.2 nM) (A, 
B) or TNF-α (25 ng ml-1) (C, D) in the presence of EPA (50 μM) alone, or in the presence of curcumin 
(10 μg ml-1) (A, C) or GTE (10 μg ml-1) (B, D) over a 24h period as described in methods. The 
experiment was repeated three times. Differences from the negative control with no additions is 
indicated as *p<0.05 or ***p<0.001, while differences from PIF or TNF-α alone is shown as Ϯ p<0.05 
or ϮϮ p<0.01 and ϮϮϮ p<0.001. 
Figure 3. Proteasome chymotrypsin like enzyme activity in C2C12 myotubes after treatment for 24h 
with TNF-α (25 ng ml-1) (A) or PIF (4.2 nM) (B) in the absence or presence of EPA (50 μM), curcumin 
(10 μg ml-1) and GTE (10 μg ml-1) alone, or in combination. The experiment was repeated three 
times. Difference from the negative control is indicated as ** p<0.01 and *** p<0.001, while 
difference from TNF-α and PIF alone is shown as ϮϮϮ p<0.001. 
Figure 4. Western blots showing expression of the 20S proteasome subunits (A), p42 (B), MuRF1 (C) 
and MAFbx (D) after treatment with TNF-α (25 ng ml-1) for 24h alone or with EPA (50 μM), curcumin 
(10 μg ml-1) and GTE (10 μg ml-1) alone or in combination. Actin was used as a loading control. The 
densitometric analysis is the average of three separate western blots. Differences from control are 
indicated as * p<0.05, ** p<0.01 or *** p<0.001, while differences from TNF-α are shown as ϮϮ 
p<0.01 or ϮϮϮ p<0.001. 
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Figure 5. Protein synthesis in C2C12 myotubes after treatment for 4h with TNF-α (25 ng ml
-1) (A) or PIF 
(4.2 nM) (B) in the absence or presence of EPA (50 μM), curcumin (10 ug ml-1) or GTE (10 μg ml-1) 
alone or in combination. The experiment was repeated three times. Differences from the negative 
control are indicated as *p<0.05, while differences from TNF-α or PIF are shown as Ϯp<0.05 or 
ϮϮp0.01. 
Figure 6. Myotube diameter of C2C12 myotubes after treatment with TNF-α (A) or PIF (4.2 nM) alone, 
or in the presence of EPA (50 μM), curcumin (10 μg ml-1) and GTE (10 μg ml-1). Myotube diameter 
was measured on the days shown using an inverted widefield fluorescent microscope. The 
experiment was repeated three times where n=12. Differences from the negative control are shown 
as ***p<0.001, while differences from TNF-α or PIF are shown as ϮϮϮp<0.001. 
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